Altaire Pharmaceuticals, Inc. – FDA 483, Mar 9, 2017
An FDA inspection of Altaire Pharmaceuticals, Inc., a sterile ophthalmic manufacturer in Aquebogue, NY, revealed significant deficiencies across multiple areas. Observations included failures in aseptic manufacturing procedures, incomplete laboratory records, inadequate laboratory controls for microbial testing and environmental monitoring, and a lack of validated manufacturing processes. Additionally, the firm's complaint handling procedures were found to be deficient, lacking proper review and trending analysis.
ID · 6f5a38e3-831e-43d0-8235-9fde10683ff0
- 483 - 2026-04-21
- 483 - 2022-02-11
- WARNING_LETTER - 2019-04-19
- 483 - 2019-04-19
- EIR - 2017-03-09
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.